Advanced

Elevated Lp-PLA2 Levels Add Prognostic Information to The Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects.

Persson, Margaretha LU ; Hedblad, Bo LU ; Nelson, Jeanenne J and Berglund, Göran LU (2007) In Arteriosclerosis, Thrombosis and Vascular Biology 27(Apr 12). p.1411-1416
Abstract
Background-To explore potential interrelationships between lipoprotein-associated phosholipase A2 (Lp-PLA(2)), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD). Methods and Results-MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmo Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA(2) activity and mass were significantly higher in subjects with MetS. Lp-PLA(2) activity compared with Lp-PLA(2) mass was more strongly correlated to individual components and increased more linearly with number of MetS components.... (More)
Background-To explore potential interrelationships between lipoprotein-associated phosholipase A2 (Lp-PLA(2)), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD). Methods and Results-MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmo Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA(2) activity and mass were significantly higher in subjects with MetS. Lp-PLA(2) activity compared with Lp-PLA(2) mass was more strongly correlated to individual components and increased more linearly with number of MetS components. Elevated Lp-PLA(2) activity (top compared with bottom tertile), but not elevated Lp-PLA(2) mass, increased risk for incident CVD (relative risk, RR: 1.54, 95% CI 1.07 to 2.24), as did MetS (1.42, 1.06 to 1.90) after taking possible confounders into account. Relative to those without either elevated Lp-PLA(2) activity or MetS, combination of MetS and elevated Lp-PLA(2) activity increased risk for CVD (1.97, 1.34 to 2.90). Elevated Lp-PLA(2) activity without MetS increased risk for CVD (1.40, 1.03 to 1.92) but not MetS without elevated Lp-PLA(2) activity (1.46, 0.94 to 2.27). Conclusion-Lp-PLA(2) is associated to the MetS. Higher plasma levels of Lp-PLA(2) increased risk for incident CVD regardless of MetS. The simultaneous presence of elevated Lp-PLA(2) activity and MetS may identify an especially high risk individual. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Lp-PLA(2), cohort study, metabolic syndrome, cardiovascular risk
in
Arteriosclerosis, Thrombosis and Vascular Biology
volume
27
issue
Apr 12
pages
1411 - 1416
publisher
American Heart Association
external identifiers
  • wos:000246714600027
  • scopus:34249713287
ISSN
1524-4636
DOI
10.1161/ATVBAHA.107.142679
language
English
LU publication?
yes
id
1c469c1c-5368-41b7-b4e8-15e5fd74d08e (old id 167644)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17431184&dopt=Abstract
date added to LUP
2007-07-30 09:36:30
date last changed
2017-10-22 03:37:48
@article{1c469c1c-5368-41b7-b4e8-15e5fd74d08e,
  abstract     = {Background-To explore potential interrelationships between lipoprotein-associated phosholipase A2 (Lp-PLA(2)), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD). Methods and Results-MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmo Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA(2) activity and mass were significantly higher in subjects with MetS. Lp-PLA(2) activity compared with Lp-PLA(2) mass was more strongly correlated to individual components and increased more linearly with number of MetS components. Elevated Lp-PLA(2) activity (top compared with bottom tertile), but not elevated Lp-PLA(2) mass, increased risk for incident CVD (relative risk, RR: 1.54, 95% CI 1.07 to 2.24), as did MetS (1.42, 1.06 to 1.90) after taking possible confounders into account. Relative to those without either elevated Lp-PLA(2) activity or MetS, combination of MetS and elevated Lp-PLA(2) activity increased risk for CVD (1.97, 1.34 to 2.90). Elevated Lp-PLA(2) activity without MetS increased risk for CVD (1.40, 1.03 to 1.92) but not MetS without elevated Lp-PLA(2) activity (1.46, 0.94 to 2.27). Conclusion-Lp-PLA(2) is associated to the MetS. Higher plasma levels of Lp-PLA(2) increased risk for incident CVD regardless of MetS. The simultaneous presence of elevated Lp-PLA(2) activity and MetS may identify an especially high risk individual.},
  author       = {Persson, Margaretha and Hedblad, Bo and Nelson, Jeanenne J and Berglund, Göran},
  issn         = {1524-4636},
  keyword      = {Lp-PLA(2),cohort study,metabolic syndrome,cardiovascular risk},
  language     = {eng},
  number       = {Apr 12},
  pages        = {1411--1416},
  publisher    = {American Heart Association},
  series       = {Arteriosclerosis, Thrombosis and Vascular Biology},
  title        = {Elevated Lp-PLA2 Levels Add Prognostic Information to The Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects.},
  url          = {http://dx.doi.org/10.1161/ATVBAHA.107.142679},
  volume       = {27},
  year         = {2007},
}